From Screening to Pharmacology: Lead Optimization of a CDK2 Molecular Glue Degrader

• Mapping the journey from screening to hit identification for a CDK2 molecular glue degrader
• Defining and monitoring critical parameters during lead optimization to ensure biological relevance
• Translating early activity into downstream pharmacology to achieve the desired therapeutic profile

Speakers:

Peggy Thompson

Senior Vice President, Head of Biology

Plexium Inc.